While the threat of U.S. import tariffs prompted a surge in drug production last year, that output is slated to slow across multiple geographies in 2026. | While the threat of U.S. import tariffs ...
As Sandoz looks to address the “biosimilar void” created by the scores of lucrative drugs going off patent in the next decade ...
As Lindsey Vonn’s comeback run heads toward a peak with Team USA at the upcoming 2026 Winter Olympics, Invivyd is adding the ...
Despite falling short in its recent bid to snatch Avadel from Alkermes, Lundbeck is signaling to investors that it’s not ...
After U.S. President Donald Trump took the stage at the World Economic Forum this week to tout the supposed success of his ...
As Samsung Biologics’ contract manufacturing business continues to fire on all cylinders, the CDMO has earned a unique ...
With $30 million in funding from the Coalition for Epidemic Preparedness Innovations (CEPI), Merck & Co. | The project, which involves Merck, SK Biosciences, Hilleman Laboratories and CDMO IDT ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback